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IL-2 production is decreased in systemic lupus erythematosus (SLE) patients and aﬀects T cell function and other aspects of host
immunity. Transcription factors regulating IL-2 production behave aberrantly in SLE T cells. In addition to IL-2 dysregulation,
other IL-2 family members (IL-15 and IL-21) are abnormally expressed in SLE. Decreased IL-2 production in SLE patients leads
to many immune defects such as decreased Treg production, decreased activation-induced cell death (AICD), and decreased
cytotoxicity. IL-2 deﬁciency results in systemic dysregulation of host immune responses in patients suﬀering from SLE disease.
1.Introduction
IL-2 is a multifunctional cytokine primarily produced by T
cells and is necessary for T cell activation, proliferation, and
contraction. It has been reported that production of IL-2
is decreased in patients with systemic lupus erythematosus
(SLE) and this defect aﬀects multiple aspects of host immu-
nity [1]. SLE is a complex autoimmune disease characterized
by autoantibody production and widespread inﬂammation.
Patients with this chronic disease cycle between periods of
controlled disease and disease ﬂare involving various organs
and tissue.
DefectiveIL-2productionisoneofmanyfactorsinvolved
in the immune dysregulation responsible for this disease. As
reported in patients, an IL-2 defect is observed in various
SLEmurine models andmurine models haveprovidedmuch
information about the relationship between IL-2 and SLE.
Furthermore, other IL-2 family members (IL-15 and IL-21)
have been shown to be dysregulated in SLE disease. It has
been found that the transcriptional regulators responsible
for the transcription or suppression of IL-2 production are
imbalanced in SLE T cells [2] and this explains the reduced
IL-2 levels found in SLE patients.
One of the consequences of decreased IL-2 production is
areductioninthenumberofregulatoryTcells(Treg)inthese
patients. Treg cells control expansion of autoreactive T cells
and therefore are important in inhibiting autoimmunity.
The decreased IL-2 production in SLE patients aﬀects
additional immune functions other than T cell proliferation.
Activation-induced cell death (AICD), an IL-2 regulated
process which is necessary for the down-regulation of
expanded T cell clones, is defective in SLE T cells [3, 4]. IL-
2 is also necessary for CD8+ Tc e l le ﬀector functions and the
developmentofCD8+ Tc ellmemory[5].AdefectinCD8+ T
cell cytotoxic function leads to an increased chance of intra-
cellular infection which could be deadly for SLE patients.
2. Defective IL-2Production in SLE
It has long been known that IL-2 production is defective
in SLE patients. Early in vitro studies examined SLE T
cell response to mitogens. T cells were stimulated with the
mitogen phytohemagglutinin (PHA) and it was found that
they were unable to produce high levels of IL-2; a greater
defect was observed in T cells isolated from patients with
active disease [6]. Interestingly, it was observed that PHA-
activated SLE T cells respond to exogenous IL-2 stimulation,
indicating that IL-2R expression is normal on these cells
[7]. Furthermore, it has been suggested that the IL-2R is
upregulated on T cells from SLE patients with active disease
as compared to those with inactive disease [8]. However,
it seems that the IL-2R found on these SLE T cells is not2 Journal of Biomedicine and Biotechnology
the high aﬃnity receptor and therefore these cells are not
optimally responsive to exogenous IL-2 [9].
Why do SLE T cells produce less IL-2? IL-2 production
is upregulated through an autocrine (or paracrine) loop
therefore it would seem logical that a defect in the T cell
receptor(TCR)wouldresultindecreasedtranscriptionofIL-
2. Indeed, one of the TCR components, the CD3ζ chain, is
signiﬁcantly decreased in SLE T cells [10] and in its place is
the closely related common γ chain of the immunoglobulin
receptors (FcRγ), a molecule not normally expressed in
T cells [11]. But this substitution results in increased
TCR responsiveness as evidenced by expedited calcium ﬂux
and greater tyrosine phosphorylation of TCR-associated
signaling molecules upon T cell activation [12]. Therefore
the unusual TCR conﬁguration present in SLE T cells does
not seem to contribute to the decrease in IL-2 production.
The molecular mechanism of the IL-2 defect has now
been clariﬁed. The decreased IL-2 production observed in
SLE patients is based on the relationship between the tran-
scription factors CRE-binding protein (CREB) and CRE-
modulator (CREM). These two transcription factors share a
bindingsite180basepairsupstreamoftheIL-2promoterand
are responsible for activating or repressing IL-2 production
(Figure 1). CREB occupies the binding site in resting T
cells and upon activation, it is phosphorylated (pCREB)
thereby promoting IL-2 transcription. IL-2 transcription is
repressed by the replacement of pCREB by phosphorylated
CREM (pCREM). SLE patients have higher levels of CREM
than CREB, resulting in decreased IL-2 production [2]. It is
not clear why the CREB/CREM balance is irregular in SLE
T cells, but there is evidence to suggest that the enzyme
CaMKIV which phosphorylates CREM leads to an increase
in this suppressive factor in SLE T cells [13]. Additionally,
SLE T cells have increased levels of the serine/threonine
phosphatase PP2A, the phosphatase primarily responsible
for the dephosphorylation of CREB, and this contributes to
decreased IL-2 production [14].
3. IL-2in MurineModels of SLE
There are numerous murine models for studying SLE, but as
this disease is complex and variable from patient to patient
it has not been possible to create one mouse strain that
represents the full spectrum of disease. As described above,
IL-2 is decreased in human SLE, but is this reﬂected in the
murine models?
One of the most commonly studied murine models of
SLE is the MRL/lpr strain. These mice carry the lpr mutation
in the apoptotic protein Fas. They spontaneously develop
lupus-like disease beginning at twelve weeks of age and
subsequentlydisplayskinlesions,lymphadenopathy,autoan-
tibody production, and proteinuria and often succumb to
death from glomerulonephtritis between seventeen (female)
to twenty-two weeks (male) of age. These mice exhibit
lymphoproliferation by three months of age which is not
commonly seen in patients with SLE. It was found that IL-
2 production and responsiveness is decreased in MRL/lpr
mice and as mice age (and develop severe disease), this defect















Figure 1: IL-2 transcriptional regulation in T cells. Upon T cell
activation, CREB is phosphorylated leading to IL-2 transcription.
CREM is also phosphorylated upon T cell activation and it will
displace pCREB to shut down IL-2 transcription. CaMKIV is
upregulated in SLE and it is responsible for phosphorylation of
CREM. PP2A is also upregulated in SLE and this phosphatase
dephosporylates CREB.
for humans, mitogenic or antigenic stimulation of MRL/lpr
T cells results in weak IL-2 production [15–17].
BXSB/Yaa mice develop lupus in male mice due to the
Y-linked autoimmune accelerator (Yaa) gene. Similar to
the MRL/lpr mice, the male BXSB/Yaa mice develop lupus
rapidly and ﬁfty percent will succumb to glomerulonephritis
by ﬁve months of age [18]. Like the MRL/lpr mice, male
BXSB mice display a defective IL-2 mitogenic response as
early as six weeks of age [15].
The NZB × NZW F1 murine model develops lupus
at a slower rate than the other strains mentioned. The
female NZB × NZW F1 mice will succumb to disease at
approximately eight months of age. Therefore, it is not
surprising that NZB × NZW F1 T cells do not show a
decreasedmitogenicresponseuntil7.5months,asthesemice
develop lupus-like disease slower than the other two strains
[15]. Amongst these commonly studied murine models of
SLE, the defect in IL-2 production and responsiveness is
similar to that observed in humans.
4. IL-2/IL-2R Deﬁcient Mice
Muchof whatis known about IL-2regulation of theimmune
response has been realized from studies using the IL-2 or
IL-2R knockout mice. Mice lacking IL-2 or IL-2R initially
appear normal, but by four weeks of age they develop
spontaneous autoimmune disease. The early disease dis-
played by the IL-2−/− mice is characterized by splenomegaly,
lymphadenopathy, and severe anemia. If they survive beyond
nine weeks of age, they will develop irritable bowel disease
leading to death [19, 20]. Similarly, IL-2Rβ−/− mice are
runted by four weeks of age and develop splenomegaly,
lymphadenopathy, and anemia caused by autolysis. It has
also been noted that these mice have increased serum IgG1
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Figure 2:IL-2superfamily.IL-2,IL-15,andIL-21arecloselyrelated
in receptor binding, and function. IL-2 and IL-15 bind trimeric
receptors and two of the three chains (IL-2Rβ, γc) are the same,
whileeachcytokinebindsauniquethirdcomponentofthereceptor
(IL-2α or IL-15α, respectively). The dimeric IL-21R consists of the
γc chain, shared with IL-2R and IL-15R, and a unique chain, IL-
21R.AllthreecytokinesutilizetheJanuskinasessignalingmolecules
JAK1 and JAK3. IL-2 and IL-21 can activate STAT1/3/5 while IL-15
is only known to activate STAT5. While IL-2 and IL-21 can activate
multiple STAT family members, IL-2 primarily signals through
STAT5 homodimers whereas IL-21 mostly signals through STAT3
homodimers.
not develop irritable bowel disease. Nevertheless, these mice
only survive about twelve weeks before succumbing to severe
autoimmunity [21].
Ithasmorerecentlybeendiscoveredthatthelymphopro-
liferation observed in the IL-2/IL-2R−/− mice is due to the
greatly reduced number of regulatory T cells (Treg) found in
the periphery [22]. Similarly, regulatory T cells are decreased
in SLE patients (discussed in Section 6). Unlike the knockout
mice, SLE patients do not exhibit extreme lymphoprolifer-
ation but they do have some, albeit reduced, levels of IL-2.
Nevertheless, IL-2/IL-2R deﬁcient mice present with many
of the other characteristics observed in SLE patients, such as
autoantibody production, lymphadenopathy, and decreased
Treg cells.
5.Other IL-2 FamilyMembersandSLE
Since IL-2 is integral to maintaining a healthy immune
system, it is not surprising there is some redundancy of IL-
2 function in host immunity. The IL-2 superfamily consists
of IL-2, IL-15, and IL-21 (Figure 2). The IL-2R and IL-15R
sharetwooftheirthreereceptorchains(IL-2Rβandγc)while
the IL-21R shares the common gamma chain (γc) with the
others and binds a unique receptor chain (IL-21R). All three
cytokine receptors are associated with JAK1 and JAK3, but
IL-2 and IL-15 signal primarily through STAT5, whereas IL-
21 primarily signals through STAT3 (though it does activate
STAT5).
Similar to IL-2, IL-15 can expand T cell populations
and mice lacking IL-15 have greatly reduced numbers of
NK, NKT, IEL, and CD8+ T cells, suggesting a role for
this cytokine in development and homeostasis of these cell
populations [23]. Patients with SLE have increased serum
levels of IL-15, regardless of disease state, and this may
contribute to the pathogenesis of disease [24, 25]. IL-15
has also been observed in increased levels in synovial joints
and shown to play a role in arthritic inﬂammation due to
activation of synovial T cells [26].
IL-21 is produced by T cells and it aﬀects the function of
T, NK, NKT, and B cells [27]. IL-21 enhances NK and CD8+
T cell cytotoxicity, and overexpression of IL-21 results in an
increase in memory CD8+ T cells [28]. IL-21 production is
increased in some murine models of SLE [29] and particular
polymorphismsoftheIL-21genehavebeendescribedinSLE
patients [30]. It has been shown in the BXSB/Yaa murine
model that IL-21 is integral to SLE development as deletion
of the IL-21R in these mice prevents disease progression
[31]. While the function of IL-21 on T or NK cells may
be redundant with IL-2 or IL-15, IL-21 uniquely promotes
activationandplasmacelldiﬀerentiationofperipheralBcells
[32]. Patients with SLE have decreased IL-21R expression in
their peripheral B cells and this is associated with nephritis
and high levels of autoantibodies [33]. Additionally, IL-21 is
also necessary for activation-induced death of expanded B
cells [29, 32]. While these studies suggest a role for IL-15 and
IL-21 in SLE pathogenesis, the signiﬁcance of these cytokines
inhumanSLEdiseaseisnotclearandwarrantsfurtherstudy.
6.Regulatory TCells(Treg)andSLE
Regulatory T cells (Treg) are necessary for maintaining
tolerance to self antigens and they are able to do this by
suppressing self-reactive T cells. Natural Treg cells develop in
the thymus, but induced Treg cells can be derived from a sub-
set of activated CD4+ T cells in the periphery. Development
andhomeostasisoftheCD4+CD25+Foxp3+ Treg cellsubsetis
dependent on IL-2. Mice lacking the Treg speciﬁc transcrip-
tion factor Foxp3 completely lack Treg cells and are severely
ill due to systemic autoimmunity. Decreased IL-2 leads to a
decrease in Treg population with concurrent autoimmunity
due in part to excessive lymphoproliferation. It should be
notedthatTreg cellsarenotcompletelydependentonIL-2for
development as evidenced by the low numbers of Treg cells
present in IL-2/IL-2R knockout mice [34].
Treg c e l l sa r ed e c r e a s e di nS L Ea n dt h e r ei se v i d e n c et o
suggestthatthenumberofTreg cellsinSLEpatientsmaycon-
versely relate to the severity of disease [38]. It was observed
that in pediatric SLE patients, those with active disease had
fewerTreg cellsandthisinverselycorrelatedwiththeSystemic
Lupus Erythematosus Disease Activity Index (SLEDAI) score
andserumanti-double-strandedDNAlevels[39].Ithasbeen
reported (in adult samples) that expression of FOXP3 is
decreased in Treg cells from SLE patients with active disease
and therefore these cells function poorly as suppressors,
while patients with inactive disease express more FOXP3 in
theirTreg cellsandthesecellshavegreatersuppressoractivity.
Furthermore, in vitro stimulation through the TCR of the
FOXP3low Treg cells from patients with active disease results
in an increase in FOXP3 expression and restoration of T
cell suppressor function, thereby indicating that these cells
have a reversible defect [40]. It should be noted that though
both decreased IL-2 levels and decreased Treg cells have been4 Journal of Biomedicine and Biotechnology
observed in SLE patients, a deﬁnitive link between these two
observations has not been made.
7.Activation-InducedCellDeath(AICD)
While IL-2 is necessary for T cell activation, it is also needed
following clonal expansion to control lymphoproliferation
of a T cell clone. Following antigen stimulation through
the TCR, a speciﬁc clonal T cell population will expand
to eliminate the foreign object. Once the antigen is no
longer present, the process of AICD will destroy the excess
eﬀector cells that were expanded to ﬁght the antigen. IL-
2 is required for this controlled apoptotic mechanism, in
conjunction with costimulation through CD95, TNFR1, and
other costimulatory molecules [35, 36]. Furthermore, IL-2
regulates AICD in CD8+ T cells by downregulating IL-2Rγ as
this receptor chain is associated with the survival of the cell
[37]. It has been found that SLE patients are more resistant
to AICD due to decreased levels of intracellular TNFα and
upregulation of COX2 [3, 4].
8.IL-2andCytoxicity
IL-2 is necessary for the development of CD8+ T cell/NK
cell cytoxicity. These cell types are important for ﬁghting
infection, and cytotoxic T lymphocytes (CTLs) cells are
crucial for the destruction of virally infected cells. Some
insight into the role of IL-2 in CTL development comes
from a derivative of the IL-2Rβ−/− mouse that has thymic
transgenic expression of IL-2Rβ which results in mice
lacking the characteristic autoimmunity observed in IL-
2R−/− mice, and contains IL-2 nonresponsive T cells in the
periphery. T cells from these mice can divide a few times
following co-stimulation of the TCR, but they fail to expand
further, and are unable to properly upregulate perforin and
granzyme B, the hallmarks of CD8+ T cell cytotoxicity [43,
44]. Additional support for the IL-2 requirement in CTL
expansionandactivityisapparentifwelookatinfectiondata
from the IL-2−/− mice. Following viral infection of IL-2−/−
mice with lymphocytic choriomeningitis virus (LCMV), a
T cell response could be detected but it was signiﬁcantly
decreased,suggesting that IL-2 plays an important role in the
expansion of virus-speciﬁc CTLs [45]. These observations
indicate that IL-2 signaling is necessary for the development
of cytotoxicity.
IL-2upregulatesthecostimulatorymoleculeCD70which
is necessary for CD8 expansion. It has been demonstrated
that when CD70 is blocked and IL-2 is administered, CTL
expansion does not occur [46]. CD8+ T cells expressing the
co-stimulatory molecule CD27 preferentially secrete IL-2 in
response to antigen stimulation [47] and it has recently been
shown that CD27-driven IL-2 production in virally infected
mice stimulates CD8+ T cell survival in an autocrine manner
[48]. These data demonstrate an important role for co-
stimulatory molecules working in concert with IL-2 during
CTL activation.
It is not clear how the IL-2 defect in SLE disease aﬀects
CTL development and function. Thus far, the data has been
conﬂicting. While there is evidence suggesting a cytotoxic
Table 1: Consequences of decreased IL-2 production in SLE
disease.
(i) Decreased activation-induced cell death (AICD) [3, 4, 35–37].
(ii) Decreased number and function of Treg cells [38–40].
(iii)May lead to decreased cytotoxic activity [41, 42].
defect in some patients [41, 42], there is also data that asserts
that perforin and granzyme B are upregulated in patients
with active SLE disease [49]. As seen in many aspects of
SLE disease, there may be heterogeneity amongst patients.
AC D 8 + T cell defect in SLE patients would be relevant
because this may contribute to the increased mortality from
infections reported in these patients.
9. Conclusions
IL-2 is important for regulating T cell immunity and
therefore aﬀects many aspects of immune responses. Not
onlyisIL-2dysregulatedinSLE,buttheIL-2familymembers
IL-15 and IL-21 are also expressed aberrantly. The decreased
production of IL-2 in SLE patients most likely contributes to
various immune defects such as decreased Treg production,
decreased AICD, and potentially decreased CTL responses
(Table 1). Interestingly, the decreased FOXP3 expression in
SLE Treg cells is reversible which may be exploited for ther-
apeutic development. A potential decrease in CTL activity is
ofutmostimportanceinSLEasdecreasedcytotoxicity would
make patients more susceptible to intracellular infection.
There is evidence that SLE patients have a higher incidence
of Epstein Barr virus (EBV) infection [50] and it has been
reported that SLE patients have forty times higher viral load
and a greater repertoire of antigen-speciﬁc B cells for EBV
viralproteins[51].IL-2deﬁciencyaﬀectsmultipleregulatory
pathways in the host and in the case of SLE this contributes
to the multifaceted dysregulation of the immune response.
References
[1] M. Linker-Israeli, A. C. Bakke, R. C. Kitridou, S. Gendler,
S. Gillis, and D. A. Horwitz, “Defective production of
interleukin 1 and interleukin 2 in patients with systemic lupus
erythematosus (SLE),” Journal of Immunology, vol. 130, no. 6,
pp. 2651–2655, 1983.
[ 2 ] E .E .S o l o m o u ,Y . - T .J u a n g,M .F .G o u r l e y ,G .M .K a m m e r ,a n d
G. C. Tsokos, “Molecular basis of deﬁcient IL-2 production
in T cells from patients with systemic lupus erythematosus,”
Journal of Immunology, vol. 166, no. 6, pp. 4216–4222, 2001.
[3] B. Kovacs, D. Vassilopoulos, S. A. Vogelgesang, and G. C.
T s o k o s ,“ D e f e c t i v eC D 3 - m e d i a t e dc e l ld e a t hi na c t i v a t e dT
cells from patients with systemic lupus erythematosus: role of
decreased intracellular TNF-alpha,” Clinical Immunology and
Immunopathology, vol. 81, no. 3, pp. 293–302, 1996.
[4] L. Xu, L. Zhang, Y. Yi, H.-K. Kang, and S. K. Datta,
“Human lupus T cells resist inactivation and escape death by
upregulatingCOX-2,”NatureMedicine,vol.10,no.4,pp.411–
415, 2004.
[5] M. A. Williams, A. J. Tyznik, and M. J. Bevan, “Interleukin-2
signals during priming are required for secondary expansionJournal of Biomedicine and Biotechnology 5
of CD8+ memory T cells,” Nature, vol. 441, no. 7095, pp. 890–
893, 2006.
[6] J. Alcocer-Varela and D. Alarcon-Segovia, “Decreased produc-
tion of and response to interleukin-2 by cultured lymphocytes
from patients with systemic lupus erythematosus,” Journal of
Clinical Investigation, vol. 69, no. 6, pp. 1388–1392, 1982.
[7] P. de Faucal, A. Godard, M. A. Peyrat, J. F. Moreau, and
J. P. Soulillou, “Impaired IL2 production by lymphocytes
of patients with systemic lupus erythematosus,” Annales
d’Immunologie, vol. 135D, no. 2, pp. 161–172, 1984.
[ 8 ]D .R .W i g f a l l ,R .S .S a k a i ,D .J .W a l l a c e ,a n dS .C .J o r -
dan, “Interleukin-2 receptor expression in peripheral blood
lymphocytes from systemic lupus erythematosus patients:
relationship to clinical activity,” Clinical Immunology and
Immunopathology, vol. 47, no. 3, pp. 354–362, 1988.
[9] H. Ishida, S. Kumagai, H. Umehara, et al., “Impaired expres-
sion of high aﬃnity interleukin 2 receptors on activated lym-
phocytes from patients with systemic lupus erythematosus,”
Journal of Immunology, vol. 139, no. 4, pp. 1070–1074, 1987.
[10] S. N. Liossis, X. Z. Ding, G. J. Dennis, and G. C. Tsokos,
“Altered pattern of TCR/CD3-mediated protein-tyrosyl phos-
phorylation in T cells from patients with systemic lupus
erythematosus. Deﬁcient expression of the T cell receptor zeta
chain,” The Journal of Clinical Investigation, vol. 101, no. 7, pp.
1448–1457, 1998.
[11] E. J. Enyedy, M. P. Nambiar, S.-N. C. Liossis, G. Dennis, G.
M. Kammer, and G. C. Tsokos, “Fcε receptor type I γ chain
replaces the deﬁcient T cell receptor ζ c h a i ni nTc e l l so f
patients with systemic lupus erythematosus,” Arthritis and
Rheumatism, vol. 44, no. 5, pp. 1114–1121, 2001.
[12] G. C. Tsokos, M. P. Nambiar, K. Tenbrock, and Y.-T. Juang,
“Rewiring the T-cell: signaling defects and novel prospects for
the treatment of SLE,” Trends in Immunology, vol. 24, no. 5,
pp. 259–263, 2003.
[13] Y.-T. Juang, Y. Wang, E. E. Solomou, et al., “Systemic lupus
erythematosus serumIgG increases CREMbinding to the IL-2
promoter and suppresses IL-2 production through CaMKIV,”
Journal of Clinical Investigation, vol. 115, no. 4, pp. 996–1005,
2005.
[14] C. G. Katsiari, V. C. Kyttaris, Y.-T. Juang, and G. C. Tsokos,
“Protein phosphatase 2A is a negative regulator of IL-2
production in patients with systemic lupus erythematosus,”
Journal of Clinical Investigation, vol. 115, no. 11, pp. 3193–
3204, 2005.
[ 1 5 ]A .A l t m a n ,A .N .T h e o ﬁ l o p o u l o s ,R .W e i n e r ,D .H .K a t z ,
and F. J. Dixon, “Analysis of T cell function in autoimmune
murine strains. Defects in production of and responsiveness
to interleukin 2,” Journal of Experimental Medicine, vol. 154,
no. 3, pp. 791–808, 1981.
[ 1 6 ]D .W o f s y ,E .D .M u r p h y ,J .B .R o t h s ,M .J .D a u p h i n ´ ee, S.
B. Kipper, and N. Talal, “Deﬁcient interleukin 2 activity in
MRL/Mp and C57BL/6J mice bearing the lpr gene,” Journal of
Experimental Medicine, vol. 154, no. 5, pp. 1671–1680, 1981.
[17] J.-L. Davignon, P. L. Cohen, and R. A. Eisenberg, “Rapid
T cell receptor modulation accompanies lack of in vitro
mitogenic responsiveness of double negative T cells to anti-
CD3 monoclonal antibody in MRL/Mp-lpr/lpr mice,” Journal
of Immunology, vol. 141, no. 6, pp. 1848–1854, 1988.
[18] B. Hahn and R. R. Singh, “Animal models of systemic lupus
erythematosus,” in Dubois’LupusErythematosus,D .J .W allac e,
Ed., Lippincott Williams & Wilkin, Philadelphia, Pa, USA, 7th
edition, 2007.
[19] H. Schorle, T. Holtschke, T. Hunig, A. Schimpl, and I. Horak,
“Development and function of T cells in mice rendered
interleukin-2 deﬁcient by gene targeting,” Nature, vol. 352, no.
6336, pp. 621–624, 1991.
[20] B .Sadlac k,H.M erz,H.Sc horle,A.Sc himpl,A.C.F eller ,andI.
Horak, “Ulcerative colitis-like disease in mice with a disrupted
interleukin-2 gene,” Cell, vol. 75, no. 2, pp. 253–261, 1993.
[21] H. Suzuki, T. M. Kundig, C. Furlonger, et al., “Deregulated T
cell activation and autoimmunity in mice lacking interleukin-
2r e c e p t o rβ,” Science, vol. 268, no. 5216, pp. 1472–1476, 1995.
[ 2 2 ]T .R .M a l e k ,A .Y u ,V .V i n c e k ,P .S c i b e l l i ,a n dL .K o n g ,“ C D 4
regulatory T cells prevent lethal autoimmunity in IL-2Rβ-
deﬁcient mice: implications for the nonredundant function of
IL-2,” Immunity, vol. 17, no. 2, pp. 167–178, 2002.
[ 2 3 ]M .K .K e n n e d y ,M .G l a c c u m ,S .N .B r o w n ,e ta l . ,“ R e v e r s i b l e
defects in natural killer and memory CD8 T cell lineages
in interleukin 15-deﬁcient mice,” Journal of Experimental
Medicine, vol. 191, no. 5, pp. 771–780, 2000.
[ 2 4 ]M .A r i n g e r ,G .H .S t u m m v o l l ,G .S t e i n e r ,e ta l . ,“ S e r u m
interleukin-15 is elevated in systemic lupus erythematosus,”
Rheumatology, vol. 40, no. 8, pp. 876–881, 2001.
[25] L. Baranda, H. de la Fuente, E. Layseca-Espinosa, et al., “IL-
15 and IL-15R in leucocytes from patients with systemic lupus
erythematosus,” Rheumatology, vol. 44, no. 12, pp. 1507–1513,
2005.
[26] I. B. Mcinnes, J. Al-Mughales, M. Field, et al., “The role of
interleukin-15 in T-cell migration and activation in rheuma-
toid arthritis,” Nature Medicine, vol. 2, no. 2, pp. 175–182,
1996.
[27] C. Gabay and I. B. McInnes, “The biological and clinical
importance of the ‘new generation’ cytokines in rheumatic
diseases,” Arthritis Research and Therapy, vol. 11, no. 3, article
230, 2009.
[ 2 8 ] E . - L .A l l a r d ,M . - P .H a r d y ,J .L e i g n a d i e r ,e ta l . ,“ O v e r e x p r e s s i o n
of IL-21 promotes massive CD8+ memory T cell accumula-
tion,” European Journal of Immunology, vol. 37, no. 11, pp.
3069–3077, 2007.
[29] K. Ozaki, R. Spolski, R. Ettinger, et al., “Regulation of B cell
diﬀerentiation and plasma cell generation by IL-21, a novel
inducer of Blimp-1 and Bcl-6,” Journal of Immunology, vol.
173, no. 9, pp. 5361–5371, 2004.
[30] A. H. Sawalha, K. M. Kaufman, J. A. Kelly, et al., “Genetic
association of interleukin-21 polymorphisms with systemic
lupus erythematosus,” Annals of the Rheumatic Diseases, vol.
67, no. 4, pp. 458–461, 2008.
[ 3 1 ] J .A .B u b i e r ,T .J .S p r o u l e ,O .F o r e m a n ,e ta l . ,“ Ac ri t i c a lr o l ef o r
IL-21 receptor signaling in the pathogenesis of systemic lupus
erythematosus in BXSB-Yaa mice,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 106,
no. 5, pp. 1518–1523, 2009.
[32] R. Ettinger, S. Kuchen, and P. E. Lipsky, “The role of IL-
21 in regulating B-cell function in health and disease,”
Immunological Reviews, vol. 223, no. 1, pp. 60–86, 2008.
[33] H. Mitoma, T. Horiuchi, Y. Kimoto, et al., “Decreased expres-
sion of interleukin-21 receptor on peripheral B lymphocytes
in systemic lupus erythematosus,” International Journal of
Molecular Medicine, vol. 16, no. 4, pp. 609–615, 2005.
[34] L. M. D’Cruz and L. Klein, “Development and function
of agonist-induced CD25+Foxp3+ regulatory T cells in the
absence of interleukin 2 signaling,” Nature Immunology, vol.
6, no. 11, pp. 1152–1159, 2005.
[35] J. Dhein, H. Walczak, C. Baumler, K.-M. Debatin, and P.
H. Krammer, “Autocrine T-cell suicide mediated by APO-
1/(Fas/CD95),” Nature, vol. 373, no. 6513, pp. 438–441, 1995.
[36] H.-K. Sytwu, R. S. Liblau, and H. O. McDevitt, “The roles of
Fas/APO-1(CD95)andTNFinantigen-inducedprogrammed6 Journal of Biomedicine and Biotechnology
cell death in T cell receptor transgenic mice,” Immunity, vol. 5,
no. 1, pp. 17–30, 1996.
[ 3 7 ]Z .D a i ,A .A r a k e l o v ,M .W a g e n e r ,B .T .K o n i e c z n y ,a n dF .G .
Lakkis, “The role of the common cytokine receptor γ-chain
in regulating IL-2- dependent, activation-induced CD8+ Tc ell
death,” Journal of Immunology, vol. 163, no. 6, pp. 3131–3137,
1999.
[38] A. La Cava, “T-regulatory cells in systemic lupus erythemato-
sus,” Lupus, vol. 17, no. 5, pp. 421–425, 2008.
[39] J.-H. Lee, L.-C. Wang, Y.-T. Lin, Y.-H. Yang, D.-T. Lin, and B.-
L. Chiang, “Inverse correlation between CD4+ regulatory T-
cell population and autoantibody levels in paediatric patients
withsystemiclupuserythematosus,”Immunology,vol.117,no.
2, pp. 280–286, 2006.
[40] X. Valencia, C. Yarboro, G. Illei, and P. E. Lipsky, “Deﬁcient
CD4+CD25high T regulatory cell function in patients with
active systemic lupus erythematosus,” Journal of Immunology,
vol. 178, no. 4, pp. 2579–2588, 2007.
[41] C. S. Via, G. C. Tsokos, B. Bermas, M. Clerici, and G. M.
Shearer, “T cell-antigen-presenting cell interactions in human
systemic lupus erythematosus: evidence for heterogeneous
expression of multiple defects,” Journal of Immunology, vol.
151, no. 7, pp. 3914–3922, 1993.
[42] G. C. Tsokos, “Overview of cellular immune function in sys-
temic lupus erythematosus,” in Systemic Lupus Erythematosus,
R.G.Lahita,Ed.,pp.29–92,AcademicPress,4thedition,2004.
[43] T. R. Malek, B. O. Porter, E. K. Codias, P. Scibelli, and
A. Yu, “Normal lymphoid homeostasis and lack of lethal
autoimmunity in mice containing mature T cells with severely
impaired IL-2 receptors,” Journal of Immunology, vol. 164, no.
6, pp. 2905–2914, 2000.
[44] T. R. Malek, A. Yu, P. Scibelli, M. G. Lichtenheld, and E. K.
Codias, “Broad programming by IL-2 receptor signaling for
extended growth to multiple cytokines and functional mat-
uration of antigen-activated T cells,” Journal of Immunology,
vol. 166, no. 3, pp. 1675–1683, 2001.
[45] L. P. Cousens, J. S. Orange, and C. A. Biron, “Endogenous
IL-2 contributes to T cell expansion and IFN-γ production
during lymphocytic choriomeningitis virus infection,” Journal
of Immunology, vol. 155, no. 12, pp. 5690–5699, 1995.
[46] J. Huang, K. W. Kerstann, M. Ahmadzadeh, et al., “Modula-
tion by IL-2 of CD70 and CD27 expression on CD8+ Tc e l l s :
importance for the therapeutic eﬀectiveness of cell transfer
immunotherapy,” Journal of Immunology, vol. 176, no. 12, pp.
7726–7735, 2006.
[47] A. F. Ochsenbein, S. R. Riddell, M. Brown, et al., “CD27
expressionpromoteslong-termsurvivaloffunctionaleﬀector-
memory CD8+ cytotoxic T lymphocytes in HIV-infected
patients,” Journal of Experimental Medicine, vol. 200, no. 11,
pp. 1407–1417, 2004.
[48] V. Peperzak, Y. Xiao, E. A. M. Veraar, and J. Borst, “CD27
sustainssurvivalofCTLsinvirus-infectednonlymphoidtissue
in mice by inducing autocrine IL-2 production,” Journal of
Clinical Investigation, vol. 120, no. 1, pp. 168–178, 2010.
[49] P. Blanco, V. Pitard, J.-F. Viallard, J.-L. Taupin, J.-L. Pellegrin,
and J.-F. Moreau, “Increase in activated CD8+ Tl y m p h o c y t e s
expressing perforin and granzyme B correlates with disease
activity in patients with systemic lupus erythematosus,”
Arthritis and Rheumatism, vol. 52, no. 1, pp. 201–211, 2005.
[50] J. A. James, K. M. Kaufman, A. D. Farris, E. Taylor-Albert,
T. J. A. Lehman, and J. B. Harley, “An increased prevalence
of Epstein-Barr virus infection in young patients suggests a
possible etiology for systemic lupus erythematosus,” Journal
of Clinical Investigation, vol. 100, no. 12, pp. 3019–3026, 1997.
[51] B.D.Poole,A.K.Templeton,J.M.Guthridge,E.J.Brown,J.B.
Harley, and J. A. James, “Aberrant Epstein-Barr viral infection
in systemic lupus erythematosus,” Autoimmunity Reviews, vol.
8, no. 4, pp. 337–342, 2009.